Zanubrutinib-induced liver injury: a case report and literature review

Zanubrutinib-induced liver injury: a case report and literature review

Abstract Background Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib....

Full description

Bibliographic Details
Main Authors: Edmond Atallah, Pramudi Wijayasiri, Nicole Cianci, Khorrum Abdullah, Abhik Mukherjee, Guruprasad P. Aithal
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Gastroenterology
Subjects:
Zanubrutinib
hepatotoxicity
Drug-induced liver injury
Case report
RUCAM
Online Access:https://doi.org/10.1186/s12876-021-01825-2

Internet

https://doi.org/10.1186/s12876-021-01825-2

Similar Items